MedTrace Logo

Deprescribing Tamsulosin in Older Men

NCT05415748 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2025-08-22

Study results available
· View outcomes & findings →

Summary

This is a pilot 12-week randomized, placebo-controlled N-of-1 deprescribing trial among older men receiving chronic tamsulosin therapy for lower urinary tract symptoms attributed to benign prostatic hyperplasia.

Conditions

  • Benign Prostatic Hyperplasia
  • Lower Urinary Tract Symptoms

Interventions

DRUG

Tamsulosin

Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks

DRUG

Placebo

Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Benjmain N Breyer, MD, MAS · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-18
Primary Completion
2022-07-22
Completion
2022-07-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05415748 on ClinicalTrials.gov